CONTEXT: Castration-resistant prostate cancer (CRPC) refers to patients who no longer
respond to surgical or medical castration. Standard treatment options are limited …

Simple Summary Castration-resistant prostate cancer (CRPC) remains a significant medical
challenge, even with recent advancements in diagnosis and treatment. To improve patient …

Context Until recently, the only approved agent for metastatic castration-resistant prostate
cancer (mCRPC) was docetaxel chemotherapy. But over the last 5 years, significant …

Although the long natural history of prostate cancer presents challenges in the development
of novel therapeutics, major contributions have been observed recently. A better …

Abstract Context Prostate cancer (PCa) is the most common noncutaneous malignancy and
the second leading cause of cancer mortality amongst men in the Western world. Up to 40 …

Prostate cancer is a leading cause of cancer death in men in developed countries. Once the
tumor has achieved a castration-refractory metastatic stage, treatment options are limited …

Background Non-metastatic castration resistant prostate cancer (M0CRPC) is a
heterogenous disease state affecting an estimated 100,000 men in the United States …

Progress in understanding the disease biology and mechanisms of castration resistance led
to significant therapeutic advancements, particularly in the setting of mCRPC in which …

Background Although there have been great advances in mechanisms and therapeutic
methods of prostate cancer, the mortality rate of prostate cancer remains high. The castration …

There have been more drugs approved by the US Food and Drug Administration for the
treatment of castration‐resistant prostate cancer in the past 3 years than in the prior 3 …